{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:23:02Z","timestamp":1793157782671,"version":"4.5.0"},"reference-count":86,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec id=\"ab-dcs240001-1\"><jats:title>Importance<\/jats:title><jats:p>Evidence-based recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients in the US are needed.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dcs240001-2\"><jats:title>Objective<\/jats:title><jats:p>To develop evidence- and consensus-based expert recommendations on the diagnosis and treatment of vitiligo in young patients.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dcs240001-3\"><jats:title>Evidence Review<\/jats:title><jats:p>A process was developed to produce consensus recommendations addressing questions regarding pediatric vitiligo. A librarian-conducted literature review was performed using articles that met the inclusion criteria: published in English, containing primary data (including meta-analysis) and pediatric-specific data, and analysis of 6 or more patients. Included articles were graded by the Strength of Recommendation Taxonomy criteria and Oxford Centre for Evidence-based Medicine\u2019s Levels of Evidence and Grades of Recommendation. Research questions were reviewed on May 9, 2022, through a video conference. One month after the conference, participants participated in an online survey documenting their level of agreement with the generated statements, using a 5-point Likert scale.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dcs240001-4\"><jats:title>Findings<\/jats:title><jats:p>Articles on topical corticosteroids and\/or topical calcineurin inhibitors (n\u2009=\u200950), topical Janus kinase inhibitors (n\u2009=\u20095), pseudocatalase (n\u2009=\u20092), and microdermabrasion (n\u2009=\u20092) met inclusion criteria. Forty-two recommendations were made on the diagnosis of vitiligo and optimal topical therapeutics, with 33 recommendations obtaining a 70% or greater composite agreement and strong agreement. Topical calcineurin inhibitors twice daily, topical corticosteroids with time limitation due to atrophy risk, and topical ruxolitinib, 1.5%, cream\u2014used off-label for patients younger than 12 years and limited to nonsegmental vitiligo\u2014were identified as evidence-based first-line therapies in the management of pediatric and adolescent patients, with specific guidance on age-based data, minimum therapeutic trial of 6 months or greater, prolonged therapy to prevent recurrence, and the positive benefit of coordinated use of UV therapeutic sources.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dcs240001-5\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Evidence supports the use of topical calcineurin inhibitors, topical corticosteroids, and topical Janus kinase inhibitors as effective therapeutics for vitiligo in pediatric, adolescent, and young adult patients, with specific decisions on choice of agent based on factors such as site location, body surface area, and age.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.0021","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:21:17Z","timestamp":1710343277000},"page":"453","source":"Crossref","is-referenced-by-count":45,"title":["Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients"],"prefix":"10.1001","volume":"160","author":[{"given":"Yael","family":"Renert-Yuval","sequence":"first","affiliation":[{"name":"Department of Dermatology and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Pediatric Dermatology Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva, Israel, and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"H\u00f4pital Henri Mondor, Department of Dermatology and Universit\u00e9 Paris Est Cr\u00e9teil, Epidemiology in Dermatology and Evaluation of Therapeutics, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Grimes","sequence":"additional","affiliation":[{"name":"Departments of Dermatology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"Dermatology and Pediatrics, University of California, San Diego School of Medicine, San Diego"},{"name":"Pediatrics and Adolescent Dermatology, Rady Children\u2019s Hospital, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Castelo-Soccio","sequence":"additional","affiliation":[{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases, US National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas"},{"name":"Innovative Dermatology, Plano, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Walsh","sequence":"additional","affiliation":[{"name":"Hunter College Library, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Royal Children\u2019s Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weingarten","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Narla","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Luke\u2019s University Health Network, Easton, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Gardner","sequence":"additional","affiliation":[{"name":"Vitiligo Support International, Lynchburg, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Siegel","sequence":"additional","affiliation":[{"name":"Pediatric Dermatology Research Alliance, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Ibad","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette B.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"dcs240001r1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000528180","article-title":"Prevalence of vitiligo among children and adolescents in the United States.","volume":"239","author":"Patel","year":"2023","journal-title":"Dermatology"},{"issue":"3","key":"dcs240001r2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/pde.2014.31.issue-3","article-title":"Quality of life impairment in children and adolescents with vitiligo.","volume":"31","author":"Silverberg","year":"2014","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"dcs240001r3","first-page":"327","article-title":"Prevalence of depression in vitiligo patients.","volume":"11","author":"Al-Harbi","year":"2013","journal-title":"Skinmed"},{"issue":"2","key":"dcs240001r4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/ijd.v59.2","article-title":"Clinical and epidemiological characteristics of childhood vitiligo: a study of 701 patients from Brazil.","volume":"59","author":"Martins","year":"2020","journal-title":"Int J Dermatol"},{"issue":"3","key":"dcs240001r5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaad.2015.05.038","article-title":"Early-onset childhood vitiligo is associated with a more extensive and progressive course.","volume":"73","author":"Mu","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"dcs240001r6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-4126","article-title":"A practical approach to the diagnosis and treatment of vitiligo in children.","volume":"138","author":"Ezzedine","year":"2016","journal-title":"Pediatrics"},{"issue":"6","key":"dcs240001r7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/exd.2019.28.issue-6","article-title":"Vitiligo as a skin memory disease: the need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells.","volume":"28","author":"Boniface","year":"2019","journal-title":"Exp Dermatol"},{"issue":"3","key":"dcs240001r8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up.","volume":"65","author":"Alikhan","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"dcs240001r9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/archdermatol.2011.351","article-title":"Halo nevi association in nonsegmental vitiligo affects age at onset and depigmentation pattern.","volume":"148","author":"Ezzedine","year":"2012","journal-title":"Arch Dermatol"},{"issue":"5","key":"dcs240001r10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis.","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"8","key":"dcs240001r11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1001\/jamadermatol.2013.4228","article-title":"Association between vitiligo and atopic disorders: a pilot study.","volume":"149","author":"Silverberg","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dcs240001r12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bjd.2012.168.issue-1","article-title":"Guidelines for the management of vitiligo: the European Dermatology Forum consensus.","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"issue":"4","key":"dcs240001r13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0190-9622(96)90691-X","article-title":"Guidelines of care for vitiligo.","volume":"35","author":"Drake","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"5 Pt 1","key":"dcs240001r14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0190-9622(87)70119-4","article-title":"Childhood vitiligo.","volume":"16","author":"Halder","year":"1987","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"dcs240001r15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3122\/jabfm.17.1.59","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature.","volume":"69","author":"Ebell","year":"2004","journal-title":"Am Fam Physician"},{"issue":"9988","key":"dcs240001r17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo.","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"dcs240001r18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1365-2133.2008.08881.x","article-title":"Guideline for the diagnosis and management of vitiligo.","volume":"159","author":"Gawkrodger","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"dcs240001r19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/ppp.2010.26.issue-5","article-title":"Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study.","volume":"26","author":"Majid","year":"2010","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"6","key":"dcs240001r20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/pde.2016.33.issue-6","article-title":"Treatment of childhood vitiligo using tacrolimus ointment with narrowband ultraviolet B phototherapy.","volume":"33","author":"Dayal","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"dcs240001r21","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/bjd.v184.5","article-title":"Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial.","volume":"184","author":"Thomas","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"dcs240001r22","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jaad.2021.01.067","article-title":"The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.","volume":"84","author":"Ju","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"dcs240001r23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/ijd.2009.48.issue-1","article-title":"Efficacy and safety of tacrolimus cream 0.1% in the treatment of vitiligo.","volume":"48","author":"Xu","year":"2009","journal-title":"Int J Dermatol"},{"issue":"2","key":"dcs240001r24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"dcs240001r26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/archderm.139.5.581","article-title":"A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.","volume":"139","author":"Lepe","year":"2003","journal-title":"Arch Dermatol"},{"issue":"3","key":"dcs240001r27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/bjd.2011.165.issue-3","article-title":"A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0\u00b71% vs. clobetasol propionate 0\u00b705% in childhood vitiligo.","volume":"165","author":"Ho","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"dcs240001r29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/archderm.139.5.571","article-title":"Successful treatment of vitiligo with 0.1% tacrolimus ointment.","volume":"139","author":"Travis","year":"2003","journal-title":"Arch Dermatol"},{"issue":"5","key":"dcs240001r30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1067\/mjd.2002.126250","article-title":"Topical tacrolimus for repigmentation of vitiligo.","volume":"47","author":"Grimes","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"dcs240001r31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis.","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"7","key":"dcs240001r32","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jid.2020.12.028","article-title":"Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study.","volume":"141","author":"Seneschal","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"3","key":"dcs240001r33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000099592","article-title":"Pimecrolimus cream in repigmentation of vitiligo.","volume":"214","author":"Seirafi","year":"2007","journal-title":"Dermatology"},{"issue":"3","key":"dcs240001r34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/09546630903266761","article-title":"Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo.","volume":"21","author":"K\u00f6se","year":"2010","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"dcs240001r35","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jaad.2004.05.036","article-title":"Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases.","volume":"51","author":"Silverberg","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"dcs240001r36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jdv.2009.23.issue-8","article-title":"Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.","volume":"23","author":"Radakovic","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"dcs240001r37","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo.","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"dcs240001r38","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s40261-019-00845-x","article-title":"Efficacy of the topical calcineurin inhibitors tacrolimus and pimecrolimus in the treatment of vitiligo in infants under 2 years of age: a randomized, open-label pilot study.","volume":"39","author":"Hu","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"5","key":"dcs240001r39","first-page":"507","article-title":"Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color.","volume":"10","author":"Silverberg","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"dcs240001r40","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study.","volume":"135","author":"Cavali\u00e9","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"3","key":"dcs240001r41","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/pcr.2012.25.issue-3","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"issue":"18","key":"dcs240001r42","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.","volume":"362","author":"Jin","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"dcs240001r43","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.autrev.2011.02.004","article-title":"Immunopathogenesis of vitiligo.","volume":"10","author":"Sandoval-Cruz","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"4","key":"dcs240001r44","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.abd.2021.09.008","article-title":"Update on the pathogenesis of vitiligo.","volume":"97","author":"Marchioro","year":"2022","journal-title":"An Bras Dermatol"},{"key":"dcs240001r45","doi-asserted-by":"publisher","DOI":"10.1002\/eji.v54.4","article-title":"The IFN-?-CXCL9\/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment.","author":"Liu","year":"2023","journal-title":"Eur J Immunol"},{"issue":"174","key":"dcs240001r46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005127","article-title":"Mutant HSP70 reverses autoimmune depigmentation in vitiligo.","volume":"5","author":"Mosenson","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"dcs240001r47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13619-022-00132-9","article-title":"A mouse model of vitiligo based on endogenous auto-reactive CD8?+?T cell targeting skin melanocyte.","volume":"11","author":"Chen","year":"2022","journal-title":"Cell Regen"},{"issue":"3","key":"dcs240001r48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/bjd.2012.166.issue-3","article-title":"Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo.","volume":"166","author":"Ezzedine","year":"2012","journal-title":"Br J Dermatol"},{"key":"dcs240001r49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13671-014-0098-6","article-title":"The epidemiology of vitiligo.","volume":"4","author":"Silverberg","year":"2015","journal-title":"Curr Dermatol Rep"},{"issue":"3","key":"dcs240001r50","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4103\/2229-5178.115539","article-title":"A clinical study of the spectrum of vitiligo in children versus adults and its associations.","volume":"4","author":"Prakash","year":"2013","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"dcs240001r51","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1111\/ajd.v62.1","article-title":"Adults with a more extensive body involvement, moderate to extremely severe vitiligo and a prolonged clinical course have an early onset in childhood in addition to other prognostic factors as compared to individuals with later-onset vitiligo.","volume":"62","author":"Mahajan","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"2","key":"dcs240001r52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jaad.2006.08.017","article-title":"High-potency steroid use in children with vitiligo: a retrospective study.","volume":"56","author":"Kwinter","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"dcs240001r53","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/jdv.2008.22.issue-11","article-title":"A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase\/dismutase superoxide in vitiligo.","volume":"22","author":"Sanclemente","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"dcs240001r54","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/archderm.135.9.1061","article-title":"Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo.","volume":"135","author":"Westerhof","year":"1999","journal-title":"Arch Dermatol"},{"issue":"3","key":"dcs240001r55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/ijd.1995.34.issue-3","article-title":"Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo.","volume":"34","author":"Khalid","year":"1995","journal-title":"Int J Dermatol"},{"issue":"2","key":"dcs240001r56","first-page":"238","article-title":"[Corticosteroid-induced glaucoma following treatment of the periorbital region].","volume":"99","author":"Katsushima","year":"1995","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"2","key":"dcs240001r57","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1203475415615325","article-title":"Screening of Glaucoma or Cataract Prevalence in Vitiligo Patients and Its Relationship With Periorbital Steroid Use.","volume":"20","author":"Khurrum","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"dcs240001r58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/pde.2004.21.issue-4","article-title":"Calcipotriene and corticosteroid combination therapy for vitiligo.","volume":"21","author":"Travis","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"dcs240001r59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"dcs240001r60","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaad.2021.06.873","article-title":"Janus kinase inhibitors in dermatology: Part II. A comprehensive review.","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"dcs240001r61","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","article-title":"Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies.","volume":"22","author":"Gong","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"dcs240001r62","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream.","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"dcs240001r64","doi-asserted-by":"publisher","first-page":"AB36","DOI":"10.1016\/j.jaad.2021.06.169","article-title":"Maintenance of repigmentation after discontinuation of ruxolitinib cream in patients with vitiligo.","volume":"85","author":"Rosmarin","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"dcs240001r65","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000513938","article-title":"Topical tofacitinib: a Janus kinase inhibitor for the treatment of vitiligo in an adolescent patient.","volume":"13","author":"Berbert Ferreira","year":"2021","journal-title":"Case Rep Dermatol"},{"issue":"10244","key":"dcs240001r66","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"dcs240001r67","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"dcs240001r68","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"dcs240001r69","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/sj.jidsp.5640189","article-title":"In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase.","volume":"4","author":"Schallreuter","year":"1999","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"7","key":"dcs240001r70","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/ijd.2008.47.issue-7","article-title":"From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo.","volume":"47","author":"Schallreuter","year":"2008","journal-title":"Int J Dermatol"},{"issue":"5","key":"dcs240001r71","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1046\/j.1365-2230.2003.01351_1.x","article-title":"Effectiveness of pseudocatalase formulations in vitiligo.","volume":"28","author":"Schallreuter","year":"2003","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"dcs240001r72","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1046\/j.1365-2230.2002.01142.x","article-title":"Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study.","volume":"27","author":"Patel","year":"2002","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"dcs240001r73","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/bjd.2009.161.issue-4","article-title":"A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo.","volume":"161","author":"Bakis-Petsoglou","year":"2009","journal-title":"Br J Dermatol"},{"issue":"16","key":"dcs240001r74","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2016.12399","article-title":"Interventions for Vitiligo.","volume":"316","author":"Ezzedine","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"dcs240001r75","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/pde.v37.4","article-title":"Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.","volume":"37","author":"Olamiju","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"dcs240001r76","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdcr.2021.07.021","article-title":"Repigmentation of vitiligo-associated eyelash leukotrichia with topical tofacitinib.","volume":"16","author":"Kim","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"4","key":"dcs240001r77","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/jocd.v19.4","article-title":"Efficacy of microneedling combined with tacrolimus versus either one alone for vitiligo treatment.","volume":"19","author":"Ebrahim","year":"2020","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"dcs240001r78","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/09546630601028711","article-title":"Topical pimecrolimus: a new horizon for vitiligo treatment?","volume":"17","author":"Sendur","year":"2006","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"dcs240001r79","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jde.2010.37.issue-2","article-title":"Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo.","volume":"37","author":"Lo","year":"2010","journal-title":"J Dermatol"},{"issue":"4","key":"dcs240001r80","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/bjd.20137","article-title":"Development of a shared decision-making tool in vitiligo: an international study.","volume":"185","author":"Shourick","year":"2021","journal-title":"Br J Dermatol"},{"key":"dcs240001r81","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2147\/CLEP.S331287","article-title":"Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: final results from the extension of the cohort study protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE).","volume":"13","author":"Arana","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"4","key":"dcs240001r82","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1001\/archderm.144.4.560","article-title":"Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus.","volume":"144","author":"Mikhail","year":"2008","journal-title":"Arch Dermatol"},{"issue":"5","key":"dcs240001r83","first-page":"256","article-title":"Once-daily application of calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for repigmentation of facial vitiligo.","volume":"88","author":"Newman","year":"2011","journal-title":"Cutis"},{"issue":"10290","key":"dcs240001r84","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"dcs240001r85","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/pde.2009.26.issue-3","article-title":"The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study.","volume":"26","author":"Farajzadeh","year":"2009","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"dcs240001r86","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/jocd.v19.6","article-title":"Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo.","volume":"19","author":"Abd-Elazim","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"dcs240001r28","author":"Silverberg","year":"2022"},{"key":"dcs240001r16","unstructured":"Center for Evidence-based Medicine. Levels of evidence. Accessed December 23, 2023. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence"},{"key":"dcs240001r25","doi-asserted-by":"crossref","unstructured":"Taieb? A, Picardo? M. Clinical practice: vitiligo.? N Engl J Med. 2009;360(2):160-169. doi:10.1056\/NEJMcp0804388?","DOI":"10.1056\/NEJMcp0804388"},{"key":"dcs240001r63","unstructured":"Gavidia? M. Ruxolitinib Cream Shows Improved Efficacy, Sustained Safety in Vitiligo After Extended Follow-up. Accessed July 5, 2022. https:\/\/www.ajmc.com\/view\/ruxolitinib-cream-shows-improved-efficacy-sustained-safety-in-vitiligo-after-extended-follow-up"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2815807\/jamadermatology_renertyuval_2024_cs_240001_1713299766.63385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:10:40Z","timestamp":1713366640000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2815807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.0021","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}